AN ADDITIONAL 12 WEEKS OF RISANKIZUMAB THERAPY INDUCES CLINICAL RESPONSE IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE WHO FAILED TO ACHIEVE CLINICAL RESPONSE AFTER AN INITIAL INDUCTION PERIOD: 24-WEEK POOLED ANALYSIS OF TWO PHASE 3 STUDIES

Geert R. D'Haens  ¹     Brian Feagan  ²     William J. Sandborn  ³     Remo Panaccione  ⁴     Julian Panés  ⁵     Tadakazu Hisamatsu  ⁶     Marc Ferrante  ⁷     Ezequiel Neimark  ⁸     Peter Bossuyt     Silvio Danese     Alexandra Song     Xiaomei Liao     Tian Feng     Rachel Duan     Sofie Berg     Jean-Frédéric Colombel     Kori Wallace    
¹ Amsterdam University Medical Center,Amsterdam,Netherlands
² Alimentiv Inc.,London,Canada
³ University of California San Diego,San Diego,United States
⁴ University of Calgary,Calgary,Canada
⁵ Hospital Clínic Barcelona,Barcelona,Spain
⁶ Kyorin University School of Medicine,Tokyo,Japan
⁷ University Hospitals Leuven,Leuven,Belgium
⁸ AbbVie Inc

Session
IBD: Clinical trials III

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 1)